Back to top
more

2seventy bio, Inc. (TSVT)

(Delayed Data from NSDQ)

$4.47 USD

4.47
345,581

-0.05 (-1.11%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

by Zacks Equity Research

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Senti Biosciences, Inc. (SNTI) delivered earnings and revenue surprises of 12.50% and 27.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -44.87% and 8.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More

by Zacks Equity Research

Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

by Zacks Equity Research

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

by Zacks Equity Research

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

by Zacks Equity Research

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.

Bristol Myers (BMY), TSVT Application for Abecma Accepted

by Zacks Equity Research

Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.

bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4

by Zacks Equity Research

bluebird (BLUE) provides updates on its BLA submission for its experimental gene therapy lovo-cel and reports Q4 results. Shares are down on the same.

Harmony Biosciences Holdings, Inc. (HRMY) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View

by Zacks Equity Research

Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.

J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits

by Zacks Equity Research

A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.

How Much Upside is Left in 2seventy bio, Inc. (TSVT)? Wall Street Analysts Think 127.63%

by Zacks Equity Research

The consensus price target hints at a 127.6% upside potential for 2seventy bio, Inc. (TSVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

bluebird (BLUE) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.